The components of inventory, net as of December 31, 2022 and 2021 are presented in the following table:

During 2022, we reserved $133,006 of finished goods inventory based on our expectation that this inventory would expire before it could be sold or used in clinical trials. Also during 2022, we wrote off $50,000 of expired materials inventory. These transactions were recorded in adjustments for expired and expiring inventory in the consolidated statements of operations. No such inventory adjustments were recorded during 2021.

During 2022 and 2021, we utilized $79,582 and $27,750, respectively, of inventory for process development purposes. Also during 2022 and 2021, we allocated $103,955 and $0, respectively, of inventory for use in clinical trials. These transactions were recorded in research and development expense in the consolidated statement of operations.